COLO 205 Xenograft Model Service for Colon Cancer

The COLO 205 xenograft model is a well-established preclinical platform for evaluating therapeutic efficacy against colon adenocarcinoma, offering robust tumor take rates and predictable growth kinetics in immunodeficient hosts. At Alfa Cytology, we provide validated COLO 205 xenograft model services designed to accelerate your oncology pipeline---from compound screening and pharmacokinetic profiling to comprehensive biomarker analysis---ensuring reliable, reproducible data to support your preclinical decision-making.

Overview of COLO 205 Xenograft Model for Colon Cancer

The COLO 205 cell line was established in 1975 by Semple et al. from the ascitic fluid of a 70-year-old Caucasian male patient diagnosed with colorectal adenocarcinoma (Dukes' Classification Grade D). The patient had received prior treatment with 5-fluorouracil (5-FU) for approximately four to six weeks before sample collection. COLO 205 exhibits a mixed growth phenotype, comprising both adherent cuboidal cells and rounded refractile cells in suspension, with a hypertriploid karyotype (modal chromosome number 71--78) and characteristic marker chromosomes including an isochromosome 5q. The cell line is CSAp-negative, keratin-positive by immunoperoxidase staining, and expresses a 36,000-dalton cell surface glycoprotein related to the GA733-2 tumor-associated antigen, as well as carcinoembryonic antigen (CEA) at levels of 1.5--4.1 ng per 10^6 cells per 10 days. Notably, COLO 205 harbors a homozygous BRAF V600E mutation while remaining wild-type for KRAS and TP53, positioning it as a representative model for a genetically defined subset of colorectal tumors with distinct clinical behavior and therapeutic vulnerabilities.

In vivo, COLO 205 demonstrates robust tumorigenicity in immunodeficient murine hosts, with subcutaneous inoculation of 1x10^7 cells producing tumors at 100% frequency (5/5) within 21 days in nude mice. The xenograft model has been extensively utilized to evaluate a broad spectrum of therapeutic modalities, including conventional chemotherapeutics (5-FU, irinotecan/CPT-11), monoclonal antibodies targeting EGFR (cetuximab) or DR5 (TRA-8), and novel targeted agents such as BRAF inhibitors and CDK4/6 inhibitors (e.g., LY2835219). Additionally, orthotopic implantation of COLO 205 cells into the cecal submucosa enables investigation of local tumor progression and early metastatic events within the anatomically relevant colon microenvironment, providing a more clinically translatable platform for assessing drug penetration, stromal interactions, and resistance mechanisms. These characteristics collectively render the COLO 205 xenograft an indispensable tool for preclinical colon cancer research and therapeutic development.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting BRAF-mutant colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through BRAF V600E and WNT signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for CEA and GA733-2-related markers.

Figure 1. Effect of SCCAs on the growth of colorectal cancer cells. (Rodriguez-Enriquez, S, et al., 2021)

Cell Line Information: COLO 205

The COLO 205 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its mixed growth phenotype, BRAF V600E homozygous mutation, and derivation from a metastatic site make it unique among available colon cancer cell lines and essential for preclinical research targeting BRAF-driven colorectal carcinoma.

Our Services

Alfa Cytology leverages fully validated COLO 205 cell stocks and standardized operating procedures to deliver reproducible xenograft studies tailored to your program requirements. Our integrated preclinical platform encompasses tumor implantation, randomized group allocation, compound administration via multiple routes, and comprehensive endpoint analysis---including tumor volume monitoring, histopathology, biomarker quantification, and pharmacokinetic/pharmacodynamic correlation---providing you with publication-ready data packages and detailed study reports to advance your oncology candidates with confidence.

Workflow of COLO 205 Xenograft Model Construction

The construction of a COLO 205 xenograft model follows a systematic, multi-stage workflow that ensures reproducible tumor engraftment and reliable therapeutic evaluation. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: COLO 205 cells are expanded from authenticated, low-passage master cell banks under standardized culture conditions (RPMI 1640, 10% FBS, 37 degrees C, 5% CO2). Prior to implantation, cells undergo viability assessment (typically >95% viability by trypan blue exclusion), mycoplasma testing, and phenotypic verification to confirm genetic stability and marker expression profiles.
2. Host Selection and Acclimation: Immunodeficient mice (commonly athymic nude or NOD/SCID strains, 6--8 weeks old) are obtained from certified SPF vendors and acclimated to the vivarium environment for a minimum of 5--7 days. Animals are randomized by body weight prior to study initiation to minimize inter-group variability.
3. Tumor Cell Implantation: COLO 205 cells are harvested in log-phase growth, washed, and resuspended in serum-free medium mixed with Matrigel (typically 1:1 ratio) to enhance engraftment efficiency. For subcutaneous models, 1x10^6 to 1x10^7 cells are injected into the flank region; for orthotopic models, cells are surgically implanted into the cecal submucosa or injected via endoscopic guidance to replicate anatomical tumor localization.
4. Tumor Monitoring and Randomization: Following implantation, mice are monitored daily for general health and tumor emergence. Palpable tumors typically appear within 10--14 days. Once tumors reach a predetermined volume (commonly 100--200 mm^3), animals are randomized into treatment and control cohorts based on tumor size and body weight to ensure balanced baseline parameters.
5. Compound Administration and Dosing: Test compounds are administered according to the study design via appropriate routes (intraperitoneal, intravenous, oral gavage, subcutaneous, or osmotic pumps). Dosing schedules are optimized based on compound pharmacokinetics, with vehicle-only controls included for comparative analysis. Body weights and clinical signs are recorded throughout the dosing period.
6. Endpoint Assessment and Sample Collection: At study termination, tumors are excised and measured for final volume and weight. Tissues are processed for downstream analysis: fixed in 10% neutral buffered formalin for histopathology (H&E, IHC), snap-frozen in liquid nitrogen for molecular profiling, or stabilized in RNAlater for transcriptomic analysis. Blood samples are collected for pharmacokinetic and hematological evaluation.
7. Data Analysis and Reporting: Tumor growth inhibition (TGI), tumor growth delay (TGD), and statistical significance are calculated using appropriate parametric or non-parametric methods. Biomarker data (mRNA, protein expression) are integrated to generate mechanistic insights. A comprehensive study report is compiled, including methodology, raw data, statistical analysis, and interpretive discussion.

Figure 2: Schematic workflow illustrating the derivation and construction of the COLO 205 Xenograft Model at Alfa Cytology.

Case Study-COLO 205 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology successfully established a subcutaneous COLO 205 xenograft model to evaluate a novel targeted therapeutic agent. Tumors were established in immunodeficient mice with consistent engraftment rates and predictable growth kinetics. Following randomization, the investigational compound demonstrated dose-dependent tumor growth inhibition compared to vehicle controls, with acceptable tolerability profiles as assessed by body weight stability and clinical observation scores. Comprehensive endpoint analysis included tumor volume measurements, histopathological evaluation, and biomarker quantification to elucidate the mechanism of action. Detailed study data and statistical outcomes are available upon request under confidentiality agreement.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver high-quality COLO 205 xenograft model services that meet the exacting standards of modern oncology drug development. Our differentiated capabilities ensure that your preclinical program proceeds efficiently from study design to data delivery.

• Verified Cell Line Integrity: Validated Cell Line Repository: All COLO 205 cells are authenticated by STR profiling and routinely tested for mycoplasma contamination to ensure genetic integrity and experimental reproducibility.
• High Take Rates and Consistency: Customizable Study Designs: We offer flexible model configurations including subcutaneous, orthotopic, and metastatic variants, with tailored dosing regimens and endpoint panels to match your specific program objectives.
• Comprehensive Analytical Support: Comprehensive Endpoint Analysis: Our platform integrates tumor growth monitoring, histopathology, immunohistochemistry, biomarker quantification (RT-PCR, Western blot), and PK/PD correlation within a single service framework.
• Tailored Study Designs: Regulatory Compliance: All in vivo studies are conducted under IACUC-approved protocols in GLP-compliant facilities with SPF animal husbandry, ensuring data quality suitable for regulatory submission and peer-reviewed publication.
• Standardized Protocols: Accelerated Timelines: Standard COLO 205 xenograft studies can be initiated within 2--3 weeks of project confirmation, with real-time data access and interim reporting to support rapid decision-making.
• Dedicated Project Management: Intellectual Property Protection: Client data and proprietary compounds are handled under strict confidentiality agreements, with 100% IP ownership retained by the client upon study completion.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated COLO 205 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your preclinical research. Our scientific team is available to reach out to you with detailed protocols, feasibility assessments, and competitive pricing tailored to your project timeline. Please reach out to us today via our inquiry form or email to learn more about our COLO 205 Xenograft Model services.

For research use only. Not intended for any clinical use.